

Global Dravet Syndrome Market: Industry Analysis & Outlook

(2019-2023)

February 2019



Executive Summary


Dravet syndrome, formerly known as severe myoclonic epilepsy of infancy (SMEI), is a severe kind of epilepsy which causes seizures. High fever is usually a trigger for these seizures. It is a rare disorder that affects an estimated 1 in every 20,000–40,000 births. It usually develops in the six month of age. It is caused by loss-of-function mutations in one copy of the SCN1A gene. Patients with Dravet syndrome are not able to produce sufficient levels of functional Nav1.1 sodium channel, preventing inhibitory neurons from firing properly.

The disorder is considered orphan indication. And there are very limited treatment options available in the market. However, several therapeutics for Dravet syndrome are in pipeline. The drugs in development are getting orphan drug designation by FDA and EMA. The Dravet syndrome market in Europe and the U.S. is likely to exhibit significant growth in the next five years due to increasing research and development activities conducted by several companies. Several companies are making alliances for developing therapeutics for Dravet syndrome. Currently, the U.S and Europe are holding the potential growth for Dravet Syndrome market due to increasing R&D into new drug development for Dravet syndrome and approval for these drugs in these regions.

Key players of the market include Zogenix, Zynerba, GW Pharmaceuticals, and OPKO. Currently, only GW Pharmaceuticals' Epidiolex is commercially available. Other players are currently developing their drugs or seeking for commercial approval by FDA and EMA. Zogenix's ZX008 is expected to penetrate market in 2019 and create competition for GW Pharmaceuticals. Currently, the market is dominated by generic drugs.


Attractive orphan drug policies, increasing Dravet syndrome patient volume, development of new therapeutics and adoption of cannabidiol drugs would fuel the growth of the U.S. Dravet syndrome drug market.

The U.S. Dravet Syndrome Patient Volume Forecast (2018-2023)




- The U.S. Dravet syndrome patient volume is expected to reach ... in the year 2023, increasing from ... in the 2018, at a CAGR of ..%.
- It is expected that in 2019, ...patients of Dravet syndrome would be receiving treatment with ZX008 drug in the U.S. These numbers would start to grow rapidly with the very next year and reach ...patients in 2023.
- Epidiolex is expected to hit the U.S. market with ...treatment receiving patients in 2019. These numbers would start growing in the next year and reach ...patients in 2023.

Treated Dravet Syndrome Patients with ZX008 in the U.S. Forecast (2019-2023)




Treated Dravet Syndrome Patients with Epidiolex in the U.S. Forecast (2019-2023)




Growth of European Dravet syndrome market is likely to result from growing healthcare expenditure, development of new drugs, patient population, government initiatives...

Europe Dravet Syndrome Patient Volume Forecast (2018-2023)




- Europe Dravet syndrome patient volume is expected to reach ... in the year 2023, increasing from ... in the 2018, at a CAGR of ..%.
- It is expected that in 2020, ...patients of Dravet syndrome would be receiving treatment with ZX008 drug in the Europe. These numbers would start to grow rapidly with the very next year and reach ...patients in 2023.
- Epidiolex is expected to hit European market with ...treatment receiving patients in 2019. These numbers would start growing in the next year and reach ...patients in 2023.

Treated Dravet Syndrome Patients with ZX008 in Europe Forecast (2020-2023)



Treated Dravet Syndrome Patients with Epidiolex in Europe Forecast (2019-2023)



Disclaimer

This is a licensed product of Koncept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create other works from this report or use them in any way for commercial purpose without our prior permission. Further, you cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased the corporate license of this report.

We believe the sources are reliable, but Koncept Analytics does not warranty the accuracy or completeness of the data. The data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.

Koncept Analytics
CS-36, First Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T: +91-120-4130959
M: +91-9811715635
vikas@konceptanalytics.com

www.konceptanalytics.com